Darabi Shahram, Gorgich Enam Alhagh, Rustamzadeh Auob, Mohebi Nafiseh, Mozhdehipanah Hossein
Cellular and Molecular Research Center, Research Institute for Prevention of Non-communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.
Department of Anatomy, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran.
IBRO Neurosci Rep. 2025 Apr 23;18:672-678. doi: 10.1016/j.ibneur.2025.04.014. eCollection 2025 Jun.
Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by cognitive decline. Dyslipidemia, a risk factor for AD, may influence the expression of microRNAs (miRs) involved in AD pathogenesis. Thus, the aim of this study was to investigate the effect of dyslipidemia on the expression levels of miR-133b and miR-206 in AD patients with mild cognitive impairment. This study recruited a total of 45 subjects, who were subsequently divided into three distinct groups: the AD group (n = 15), the AD dyslipidemia group (n = 15), and the dyslipidemia group with normal cognitive status (n = 15). The Aβ serum ratio was measured using an enzyme-linked immunosorbent assay. miR expression levels were determined by RT-qPCR. Clinicopathological characteristics, including Mini-Mental State Examination (MMSE) scores, Clinical Dementia Rating (CDR), and HDL levels, were also assessed. miR-133b levels were significantly reduced in the AD dyslipidemia group compared to the other two groups (p < 0.001), while miR-206 levels were markedly elevated (p < 0.001). Spearman correlation analysis revealed that miR-133b expression levels were positively associated with the Aβ ratio (r = 0.799), MMSE scores (r = 0.578), and HDL levels (r = 0.768), while negatively associated with miR-206 levels (r = -0.461), CDR score (r = -0.539), and AD duration (r = -0.569). Conversely, miR-206 levels positively correlated with CDR and disease duration, but were inversely associated with miR-133b, MMSE, Aβ, and HDL. Serum miR-133b and miR-206 levels appear to be associated with AD pathology and clinical parameters in the early stages of the disease. The studied miR expression levels could serve as reliable biomarkers in AD patients with dyslipidemia.
阿尔茨海默病（AD）是一种以认知功能衰退为特征的进行性神经退行性疾病。血脂异常作为AD的一个危险因素，可能会影响参与AD发病机制的微小RNA（miR）的表达。因此，本研究旨在探讨血脂异常对轻度认知障碍AD患者中miR - 133b和miR - 206表达水平的影响。本研究共招募了45名受试者，随后将其分为三个不同的组：AD组（n = 15）、AD血脂异常组（n = 15）和认知状态正常的血脂异常组（n = 15）。使用酶联免疫吸附测定法测量Aβ血清比率。通过RT - qPCR测定miR表达水平。还评估了临床病理特征，包括简易精神状态检查表（MMSE）评分、临床痴呆评定量表（CDR）和高密度脂蛋白（HDL）水平。与其他两组相比，AD血脂异常组中的miR - 133b水平显著降低（p < 0.001），而miR - 206水平则显著升高（p < 0.001）。Spearman相关性分析显示，miR - 133b表达水平与Aβ比率（r = 0.799）、MMSE评分（r = 0.578）和HDL水平（r = 0.768）呈正相关，而与miR - 206水平（r = - 0.461）、CDR评分（r = - 0.539）和AD病程（r = - 0.569）呈负相关。相反，miR - 206水平与CDR和疾病病程呈正相关，但与miR - 133b、MMSE、Aβ和HDL呈负相关。血清miR - 133b和miR - 206水平似乎与疾病早期的AD病理和临床参数相关。所研究的miR表达水平可作为血脂异常AD患者的可靠生物标志物。
